María Araiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
María Araiz has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Angela M. Araujo
Biogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, Spain
1 shared publication - Carla Solé
Molecular Oncology Group, Biogipuzkoa Health Research Institute, Paseo Dr. Begiristain s/n, 20014 San Sebastian, Spain
1 shared publication - Charles Henderson Lawrie
Radcliffe Department of Medicine University of Oxford Oxford UK
1 shared publication - Erika Larrea
Molecular Oncology, Biodonostia Research Institute, 20014 San Sebastián, Spain
1 shared publication - Ibai Goicoechea
Molecular Oncology group, Biodonostia Research Institute, 20014 San Sebastián, Spain
1 shared publication - Lorea Manterola
Oncology area, Biodonostia Research Institute, San Sebastián, Spain
1 shared publication
Latest Publications
- Open Access
- 27 April 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (5) , 627
New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies
The effective and efficient management of cancer patients relies upon early diagnosis and/or the monitoring of treatment, something that is often difficult to achieve using standard tissue biopsy techniques. Biological fluids such as blood hold great possibilities as a source of non-invasive cancer biomarkers that can act as surrogate markers to biopsy-based sampling. The non-invasive nature of these “liquid biopsies” ultimately means that cancer detection may be earlier and that the ability to monitor disease progression and/or treatment response represents a paradigm shift in the treatment of cancer patients. Below, we review one of the most promising classes of circulating cancer biomarkers: microRNAs (miRNAs). In particular, we will consider their history, the controversy surrounding their origin and biology, and, most importantly, the hurdles that remain to be overcome if they are really to become part of future clinical practice.
- 27 April 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (5) , 627
Open AccessNew Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies
The effective and efficient management of cancer patients relies upon early diagnosis and/or the monitoring of treatment, something that is often difficult to achieve using standard tissue biopsy techniques. Biological fluids such as blood hold great possibilities as a source of non-invasive cancer biomarkers that can act as surrogate markers to biopsy-based sampling. The non-invasive nature of these “liquid biopsies” ultimately means that cancer detection may be earlier and that the ability to monitor disease progression and/or treatment response represents a paradigm shift in the treatment of cancer patients. Below, we review one of the most promising classes of circulating cancer biomarkers: microRNAs (miRNAs). In particular, we will consider their history, the controversy surrounding their origin and biology, and, most importantly, the hurdles that remain to be overcome if they are really to become part of future clinical practice.